Lo­cus pulls in a mod­est Se­ries B as it at­tempts to em­u­late on­col­o­gy's pre­ci­sion med­i­cine mod­el in an­tibac­te­ri­als

De­spite a sig­nif­i­cant bear mar­ket af­fect­ing the pub­lic biotech sec­tor, pri­vate com­pa­nies are still man­ag­ing to pull in VC-backed fund­ing rounds. The lat­est such round comes out of North Car­oli­na’s re­search tri­an­gle for a pre­ci­sion an­tibac­te­r­i­al drug mak­er.

Lo­cus Bio­sciences closed a $35 mil­lion Se­ries B round Wednes­day morn­ing, fea­tur­ing some no­table names in­clud­ing Ar­tis Ven­tures, Ten­cent Hold­ings, Viking Glob­al In­vestors, Dis­cov­ery In­no­va­tions and John­son and John­son In­no­va­tion, the in­vest­ment arm of J&J. CEO and co-founder Paul Garo­fo­lo told End­points News that the funds will be used to ad­vance the com­pa­ny’s lead can­di­date, dubbed LBP-EC01.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER